(Q24199041)

7

0 references

Carolyn Doree

2

0 references

Sally Hopewell

5

0 references

Marialena Trivella

4

0 references

Lise J Estcourt

object named as

Lise J Estcourt

3

0 references

Susan Brunskill

6

object named as

Susan J Brunskill

0 references

author name string

Caroline Butler

1

0 references

Michael F Murphy

Cochrane Database of Systematic Reviews

8

0 references

publication date

28 March 2013

0 references

published in

0 references

cites work

A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Design of clinical trials to evaluate the efficacy of platelet transfusion: the euroSPRITE trial for components treated with Helinx technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

The continuing risk of transfusion-transmitted infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Preclinical safety profile of plasma prepared using the INTERCEPT Blood System

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

A systematic assessment of the quality of reporting for platelet transfusion studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Transfusion medicine: looking to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Separation, identification and quantification of riboflavin and its photoproducts in blood products using high-performance liquid chromatography with fluorescence detection: a method to support pathogen reduction technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Pathogen inactivation: a new paradigm for preventing transfusion-transmitted infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Pathogen inactivation techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Pathogen inactivation of platelet concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Dose of prophylactic platelet transfusions and prevention of hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

The pathogen reduction treatment of platelets with S-59 HCl (Amotosalen) plus ultraviolet A light: genotoxicity profile and hazard assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

7 January 2021

Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

7 January 2021

Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

7 January 2021

Determination of acute lung injury after repeated platelet transfusions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009072.PUB2

7 January 2021